Digital CBT-I for Insomnia Disorder (CrEDIT)
Clinical Effectiveness of Digital CBT-I for the Treatment of Insomnia Disorder: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥22 years old
- Insomnia Disorder diagnosis
- Score ≤16 on the 8-item Sleep Condition Indicator
- > 30 minutes sleep onset latency (SOL); and/or > 30 minutes wake after sleep onset (WASO)
- Current resident of the USA
- Oral and written fluency in English
- Participant is able and willing to comply with protocol requirements, has been informed of the nature of the study, and has signed the IRB-approved informed consent form
Exclusion Criteria:
- Must not be currently receiving or be expecting to start CBT for insomnia during study participation, or have previously received CBT for insomnia in the past 12-months (self-report)
- If on psychoactive medication, including sleep medication, this must be stable for at least 5 half lives
- Past or present psychosis, schizophrenia, bipolar disorder, assessed by self-report and/or seizure disorder
- Occupation that requires alertness / caution to avoid accidents, for example long-haul driving, long distance bus driver, heavy machinery operator, air traffic controller
- Hearing or vision impairment that prevents effective use of the audio-visual content of digital CBT-I or SHE in the opinion of the investigator
- Intellectual disability or any Neurocognitive or Neurodevelopmental disorder that would prevent participants from following study procedures
- Any condition that the investigator believes would make participation in the study not in the best interest of the participant or would preclude successful completion of study activities
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Digital CBT-I
Digitally-delivered CBT for insomnia accessed via web and/or mobile app
|
A fully-automated and personalized digital intervention based on principles from cognitive behavioral therapy for insomnia.
Other Names:
|
|
Active Comparator: Sleep hygiene education
This group will receive access to sleep hygiene education delivered via digital written materials
|
Participants will be provided with sleep hygiene advice which will be delivered digitally all at once upon allocation to the SHE arm.
Participants will be able to revisit content during the trial as they wish.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Insomnia Severity Index (ISI)
Time Frame: From baseline to 10 weeks post-randomization
|
Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
|
From baseline to 10 weeks post-randomization
|
|
Change in sleep onset latency (SOL)
Time Frame: From baseline to 10 weeks post-randomization
|
Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
|
From baseline to 10 weeks post-randomization
|
|
Change in wake after sleep onset (WASO)
Time Frame: From baseline to 10 weeks post-randomization
|
Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
|
From baseline to 10 weeks post-randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insomnia Disorder remission (score <8) and response (change ≥6) on the ISI
Time Frame: 10, 16, and 24 weeks post-randomization
|
Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
|
10, 16, and 24 weeks post-randomization
|
|
Insomnia disorder remission based on the SCID Insomnia Module
Time Frame: Week -1 compared to weeks 10, 16, and 24 post-randomization
|
structured interview to assess for Insomnia Disorder
|
Week -1 compared to weeks 10, 16, and 24 post-randomization
|
|
Change in sleep diary parameters: percent sleep efficiency (SE), total sleep time (TST), total time in bed (TTIB), and total wake time (TWT)
Time Frame: From lead-in period to 10, 16, and 24 weeks post-randomization
|
Each measured in minutes by daily sleep diaries (based on the Consensus Sleep Diary)
|
From lead-in period to 10, 16, and 24 weeks post-randomization
|
|
Change in the Sleep Condition Indicator (SCI-8)
Time Frame: From baseline to weeks 10, 16, and 24 post-randomization
|
Validated questionnaire; an 8-item scale with total scores between 0 and 32 where higher scores indicate better sleep
|
From baseline to weeks 10, 16, and 24 post-randomization
|
|
Change in the Generalized Anxiety Disorder Questionnaire (GAD-7)
Time Frame: From baseline to weeks 10, 16, and 24 post-randomization
|
Validated questionnaire; a 7-item scale with total scores between 0 and 21 where higher scores indicate greater severity
|
From baseline to weeks 10, 16, and 24 post-randomization
|
|
Change in the Patient Health Questionnaire (PHQ-8)
Time Frame: From baseline to weeks 10, 16 and 24 post-randomization
|
Validated questionnaire; an 8-item scale with total scores between 0 and 24 where higher scores indicate greater severity
|
From baseline to weeks 10, 16 and 24 post-randomization
|
|
Change in the Insomnia Severity Index (ISI)
Time Frame: From baseline to weeks 16 and 24 post-randomization
|
Validated questionnaire; a 7-item scale with total scores between 0 and 28 where higher scores indicate greater severity
|
From baseline to weeks 16 and 24 post-randomization
|
|
Change in sleep onset latency (SOL)
Time Frame: From baseline to weeks 16 and 24 post-randomization
|
Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
|
From baseline to weeks 16 and 24 post-randomization
|
|
Change in wake after sleep onset (WASO)
Time Frame: From baseline to weeks 16 and 24 post-randomization
|
Measured by daily sleep diaries (based on the Consensus Sleep Diary) averaged across 10 days
|
From baseline to weeks 16 and 24 post-randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BH-S-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.